Plexin-B1 Mutation Drives Metastasis in Prostate Cancer Mouse Models.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• Metastatic prostate cancer is a leading cause of death with poorly understood molecular drivers.
• Plexins, semaphorin receptors, have varied roles in cancer progression.
• Identifying specific targets to prevent prostate cancer dissemination is crucial.

Purpose of the Study:

• To investigate the role of Plexin-B1, particularly a mutant form (P1597L), in prostate cancer metastasis.
• To determine if Plexin-B1 can be a therapeutic target for advanced prostate cancer.

Main Methods:

• Utilized two transgenic mouse models of prostate cancer (PbCre and PbCre).
• Examined the effects of prostate epithelial cell-specific expression of wild-type (WT) and mutant (P1597L) Plexin-B1.
• Assessed tumor cell invasion and metastasis.
• Investigated the involvement of the Rho/ROCK pathway and germline deletion of Plexin-B1.

Main Results:

• Prostate epithelial cell-specific expression of mutant Plexin-B1 (P1597L) significantly increased metastasis.
• Wild-type Plexin-B1 significantly decreased metastasis, indicating a switch from suppressor to promoter.
• Mutant Plexin-B1 enhanced tumor cell invasion, while WT Plexin-B1 reduced it.
• Rho/ROCK pathway inhibition and germline Plexin-B1 deletion suppressed metastasis.

Conclusions:

• Plexin-B1 plays a complex role in prostate cancer metastasis, with a specific mutation converting it to a promoter.
• Plexin-B1 signaling, especially the P1597L mutant, represents a potential therapeutic target to inhibit prostate cancer spread.